Possible involvement of sigma-1 receptors in the anti-immobility action of bupropion, a dopamine reuptake inhibitor

Fundamental and Clinical Pharmacology

Volumn 22, Issue 4, 2008, Pages 387-394

  Dhir, Ashish ^a   Kulkarni, S K ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Bupropion; Depression; Forced swim test; Sigma 1 receptors

Indexed keywords

AMFEBUTAMONE; N [2 (3,4 DICHLOROPHENYL)ETHYL] 2 DIMETHYLAMINO N METHYLETHYLAMINE; PENTAZOCINE; PROGESTERONE; RIMCAZOLE; SIGMA 1 OPIATE RECEPTOR; ANTIDEPRESSANT AGENT; CARBAZOLE DERIVATIVE; DOPAMINE UPTAKE INHIBITOR; ETHYLENEDIAMINE DERIVATIVE; NARCOTIC ANALGESIC AGENT; NEUROPROTECTIVE AGENT; SIGMA OPIATE RECEPTOR; SIGMA-1 RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG MECHANISM; DRUG POTENTIATION; FORCED SWIMMING TEST; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; ANIMAL BEHAVIOR; DRUG EFFECT; MENTAL STRESS; MOTOR ACTIVITY;

ANALGESICS, OPIOID; ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BEHAVIOR, ANIMAL; BUPROPION; CARBAZOLES; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ETHYLENEDIAMINES; MALE; MICE; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; PENTAZOCINE; PROGESTERONE; RECEPTORS, SIGMA; STRESS, PSYCHOLOGICAL;

EID: 55949115396     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2008.00605.x     Document Type: Article

References (56)

1. Dhir A., Kulkarni S.K. Involvement of nitric oxide (NO) signaling pathway in the antidepressant action of bupropion a dopamine reuptake inhibitor. Eur. J. Pharmacol. (2007) 568 177-185.
2. Kapur S., Mann J.J. Role of the dopaminergic system in depression. Biol. Psychiatry (1992) 32 1-17.
3. Renard C.E., Dailly E., Nic Dhonnchadha B.A., Hascoet M., Bourin M. Is dopamine a limiting factor of the antidepressant-like effect in the mouse forced swimming test? Prog. Neuropsychopharmacol. Biol. Psychiatry (2004) 28 1255-1259.
4. Cooper B.R., Hester T.J., Maxwell R.A. Behavioral and biochemical effects of the antidepressant bupropion (Wellbutrin), evidence for selective blockade of dopamine uptake in vivo. J. Pharmacol. Exp. Ther. (1980) 215 127-134.
5. Schonfeldt-Lecuona C., Connemann B.J., Wolf R.C., Braun M., Freudenmann R.W. Bupropion augmentation in the treatment of chronic fatigue syndrome with coexistent major depression episode. Pharmacopsychiatry (2006) 39 152-154.
6. Palamara K.L., Mogul H.R., Peterson S.J., Frishman W.H. Obesity, new perspectives and pharmacotherapies. Cardiol. Rev. (2006) 14 238-258.
7. Mooney M.E., Sofuoglu M. Bupropion for the treatment of nicotine withdrawal and craving. Expert Rev. Neurother. (2006) 6 965-981.
8. Joshi D., Singh A., Naidu P.S., Kulkarni S.K. Protective effect of bupropion on morphine tolerance and dependence in mice. Methods Find. Exp. Clin. Pharmacol. (2004) 26 623-626.
9. 1) receptor modulation in the antidepressant action of venlafaxine. Neurosci. Lett. (2007) 420 204-208.
10. Ishihara K., Sasa M. Modulation of neuronal activities in the central nervous system via sigma receptors. Nihon Shinkei Seishin Yakurigaku Zasshi (2002) 22 23-30.
11. Hashimoto K., Ishiwata K. Sigma receptor ligands, possible application as therapeutic drugs and as radiopharmaceuticals. Curr. Pharm. Des. (2006) 12 3857-3876.
12. Bermack J.E., Debonnel G. The role of sigma receptors in depression. J. Pharmacol. Sci. (2005) 97 317-336.
13. Kobayashi T., Matsuno K., Murai M., Mita S. Sigma 1 receptor subtype is involved in the facilitation of cortical dopaminergic transmission in the rat brain. Neurochem. Res. (1997) 22 1105-1109.
14. Skuza G., Rogoz Z. The synergistic effect of selective sigma receptor agonists and uncompetitive NMDA receptor antagonists in the forced swim test in rats. J. Physiol. Pharmacol. (2006) 57 217-229.
15. Ukai M., Maeda H., Nanya Y., Kameyama T., Matsuno K. Beneficial effects of acute and repeated administrations of sigma receptor agonists on behavioral despair in mice exposed to tail suspension. Pharmacol. Biochem. Behav. (1998) 61 247-252.
16. Narita N., Hashimoto K., Tomitaka S., Minabe Y. Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur. J. Pharmacol. (1996) 307 117-119.
17. Reddy D.S., Kaur G., Kulkarni S.K. Sigma (sigma1) receptor mediated anti-depressant-like effects of neurosteroids in the Porsolt forced swim test. Neuroreport (1998) 9 3069-3073.
18. Dhir A., Kulkarni S.K. Involvement of sigma (sigma1) receptors in modulating the antidepressant effect of neurosteroids (dehy-droepiandrosterone or pregnenolone) in mouse tail-suspension test. J. Psychopharmacol. (2008) (In Press).
19. Dhir A., Kulkarni S.K. Involvement of dopamine (DA)/serotonin (5-HT)/sigma (σ) receptor modulation in mediating the antidepressant action of ropinirole hydrochloride a D2/D3 dopamine receptor agonist. Brain Res. Bull. (2007) 74 58-65.
20. Dhir A., Kulkarni S.K. Involvement of L-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the anti-depressant-like effect of venlafaxine in mice. Prog. Neuropsychopharmacol. Biol. Psychiatry (2007) 31 921-925.
21. Parale M.P., Kulkarni S.K. Clonidine-induced behavioural despair in mice. Reversal Antidepressants Psychopharmacol. (1986) 89 171-174.
22. Kulkarni S.K., Mehta A.K. Purine nucleoside-mediated immobility in mice, reversal by antidepressants. Psychopharmacology (Berl) (1985) 85 460-463.
23. Dhir A., Naidu P.S., Kulkarni S.K. Protective effect of cyclo-oxygenase-2 (COX-2) inhibitors but not non-selective cyclo-oxygenase (COX)-inhibitors on ethanol withdrawal-induced behavioural changes. Addict. Biol. (2005) 10 329-335.
24. Skuza G., Rogoz Z. Sigma1 receptor antagonists attenuate antidepressant-like effect induced by co-administration of 13 di-o-tolylguanidine (DTG) and memantine in the forced swimming test in rats. Pol. J. Pharmacol. (2003) 55 1149-1152.
25. Litchfield J.T., Wilcoxon F. A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther. (1949) 96 99-113.
26. Wang J., Mack A.L., Coop A., Matsumoto R.R. Novel sigma (sigma) receptor agonists produce antidepressant-like effects in mice. Eur. Neuropsychopharmacol. (2007) 17 708-716.
27. Porsolt R.D., Bertin A., Jalfre M. Behavioral despair in mice, a primary screening test for antidepressants. Arch. Int. Phar-macodyn. Ther. (1977) 229 327-336.
28. Joca S.R., Skalisz L.L., Beijamini V., Vital M.A., Andreatini R. The antidepressive-like effect of oxcarbazepine, possible role of dopaminergic neurotransmission. Eur. Neuropsychopharmacol. (2000) 10 223-228.
29. Maj J., Rogoz Z. Pharmacological effects of venlafaxine a new antidepressant given repeatedly on the alpha 1-adrenergic dopamine and serotonin systems. J. Neural Transm. (1999) 106 197-211.
30. Ebert D., Lammers C.H. The central dopaminergic system and depression. Nervenarzt (1997) 68 545-555.
31. Siuciak J.A., Fujiwara R.A. The activity of pramipexole in the mouse forced swim test is mediated by D2 rather than D3 receptors. Psychopharmacology (2004) 175 163-169.
32. Basso A.M., Gallagher K.B., Bratcher N.A. et al. Antidepressant-like effect of D(2/3) receptor - but not D(4) receptor-activation in the rat forced swim test. Neuropsychopharmacology (2005) 30 1257-1268.
33. Yamada J., Sugimoto Y., Yamada S. Involvement of dopamine receptors in the anti-immobility effects of dopamine re-uptake inhibitors in the forced swimming test. Eur. J. Pharmacol. (2004) 504 207-211.
34. Wilkes S. Bupropion. Drugs Today (2006) 42 671-681.
35. Li S.X., Perry K.W., Wong D.T. Influence of fluoxetine on the ability of bupropion to modulate extracellular dopamine and norepinephrine concentrations in three mesocorticolimbic areas of rats. Neuropharmacology (2002) 42 181-190.
36. Ascher J.A., Cole J.O., Colin J.N. et al. Bupropion: a review of its mechanism of antidepressant activity. J. Clin. Psychiatry (1995) 56 395-401.
37. Bourin M., Colombel M.C., Redrobe J.P., Nizard J., Hascoët M., Baker G.B. Evaluation of efficacies of different classes of antidepressants in the forced swimming test in mice at different ages. Prog. Neuropsychopharmacol. Biol. Psychiatry (1998) 22 343-351.
38. 2A receptor mRNA. Biol. Pharm. Bull. (2008) 31 246-249.
39. Wesolowska A., Nikiforuk A. The selective 5-HT(6) receptor antagonist SB-399885 enhances anti-immobility action of antidepressants in rats. Eur. J. Pharmacol. (2008) 582 88-93.
40. Fossati R., Apolone G., Negri E. et al. A double-blind, placebo-controlled, randomized trial of bupropion for smoking cessation in primary care. Arch. Intern. Med. (2007) 167 1791-1797.
41. Portugal G.S., Gould T.J. Bupropion dose-dependently reverses nicotine withdrawal deficits in contextual fear conditioning. Pharmacol. Biochem. Behav. (2007) 88 179-187.
42. D'Aquila P.S., Peana A.T., Panin F., Grixoni C., Cossu M., Serra G. Reversal of antidepressant-induced dopaminergic behavioural supersensitivity after long-term chronic imipramine withdrawal. Eur. J. Pharmacol. (2003) 458 129-134.
43. Ainsworth K., Smith S.E., Zetterstrom T.S., Pei Q., Franklin M., Sharp T. Effect of antidepressant drugs on dopamine D1 and D2 receptor expression and dopamine release in the nucleus accumbens of the rat. Psychopharmacology (Berl) (1998) 140 470-477.
44. Redolat R., Vidal J., Gomez M.C., Carrasco M.C. Effects of acute bupropion administration on locomotor activity in adolescent and adult mice. Behav. Pharmacol. (2005) 16 59-62.
45. Heroux J.A., Tam S.W., De Souza E.B. Autoradiographic identification and characterization of sigma receptors in guinea pig brain using [3H]1(cyclopropylmethyl)-4-(2'-(4'-fluorophe-nyl)-2'-oxoethyl) piperidine ([3H]DuP 734) a novel sigma receptor ligand. Brain Res. (1992) 598 76-86.
46. Kitaichi K., Chabot J.G., Moebius F.F., Flandorfer A., Glossmann H., Quirion R. Expression of the purported sigma(1) receptor in the mammalian brain and its possible relevance in deficits induced by antagonism of the NMDA receptor complex as revealed using an antisense strategy. J. Chem. Neuroanat. (2000) 20 375-387.
47. Su T.P., Hayashi T. Understanding the molecular mechanism of sigma-1 receptors, towards a hypothesis that sigma-1 receptors are intracellular amplifiers for signal transduction. Curr. Med. Chem. (2003) 10 2073-2080.
48. Yagasaki Y., Numakawa T., Kumamaru E., Hayashi T., Su T.P., Kunugi H. Chronic antidepressants potentiate via sigma-1 receptors the brain-derived neurotrophic factor-induced signaling for glutamate release. J. Biol. Chem. (2006) 281 12941-12949.
49. Kinsora J.J., Corbin A., Snider B., Wiley J., Meltzer L., Heffner T. Effects of igmesine in preclinical antidepressant tests. Soc. Neurosci. (1998) 24 744.
50. Matsuno K., Kobayashi T., Tanaka M.K., Mita S. Sigma 1 receptor subtype is involved in the relief of behavioral despair in the mouse forced swimming test. Eur. J. Pharmacol. (1996) 312 267-271.
51. Takebayashi M., Hayashi T., Su T.P. A perspective on the new mechanism of antidepressants, neuritogenesis through sigma-1 receptors. Pharmacopsychiatry (2004) 37 S208-S213.
52. Stahl S.M. Antidepressant treatment of psychotic major depression, potential role of the sigma receptor. CNS Spectr. (2005) 10 319-323.
53. Rogoz Z., Skuza G. Mechanism of synergistic action following co-treatment with pramipexole and fluoxetine or sertraline in the forced swimming test in rats. Pharmacol. Rep. (2006) 58 493-500.
54. Malkesman O., Shayit M., Genud R. et al. Dehydroepiandros-terone in the nucleus accumbens is associated with early onset of depressive-behavior: a study in an animal model of childhood depression. Neuroscience (2007) 149 573-581.
55. Nestler E.J., Barrot M., DiLeone R.J., Eisch A.J., Gold S.J., Monteggia L.M. Neurobiology of depression. Neuron (2002) 34 13-25.
56. Gronier B., Debonnel G. Involvement of sigma receptors in the modulation of the glutamatergic/NMDA neurotransmission in the dopaminergic systems. Eur. J. Pharmacol. (1999) 368 183-196.